Clinical trials: STD
HIV Infections
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
Background: HIV affects millions of people. The disease may "hide" in the brain, even in people with well-controlled HIV without cancer. Then it may "wake up" and continue.
- Trial name
- NCT03239899
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Human Immunodeficiency Virus
Development of Method of Fructose Identification in Urine to Detect the Viral Infection
The goal of this research is the attempt to implement a new research method based on modern electrochemistry successes, in particular the development of the polarographic method of fructose and fructose diphosphate identification…
- Trial name
- NCT01638312
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Cardiovascular Disease, HIV Infection
Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial
The purpose of this study is to determine whether fish oil supplementation with Lovaza, formally known as Omacor will result in a significant reduction in serum triglyceride (TG), an increase in high density lipoproteins(HDL)…
- Trial name
- HALO (NCT00795717)
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Tufts University
Human Immunodeficiency Virus
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection
This is an early phase research study looking at whether an experimental gene transfer, LVsh5/C46 (also known as Cal-1), is safe and if it can protect the immune system from the effects of HIV without the use of antiretroviral…
- Trial name
- NCT01734850
- Testing
- Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Calimmune, Inc.
Human Papillomavirus Infection
Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)
This is a post-licensure safety surveillance program to detect potential safety signals in subjects, from the managed care organizations database, who have used GARDASIL™.
- Trial name
- NCT01078220
- Volunteers
- 189,629 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States
This is a two-arm study evaluating the impact of two implementation strategy conditions, dynamic implementation and routine implementation on the feasibility of delivering of Cabotegravir PrEP in low and high-volume PrEP sites in…
- Trial name
- PILLAR (NCT05374525)
- Testing
- APRETUDE, Cabotegravir OLI
- Where
- 17 sites in United States
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infection, HIV
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
The purpose of this study is to compare the neuropsychiatric adverse event profiles of etravirine 400mg once daily versus efavirenz 600mg once daily, in combination with 2 N(t)RTIs, in approximately 150 treatment-naÃ-ve HIV-1…
- Conditions
- HIV Infection, HIV, Acquired Immunodeficiency Syndrome
- Trial name
- SENSE (NCT00903682)
- Testing
- etravirine (ETR, TMC125), efavirenz (EFV)
- Where
- 33 sites in Austria, Denmark and 9 more
- Volunteers
- 157 people
- Sponsor
- Janssen-Cilag International NV
Coronary Artery Disease, Human Immunodeficiency Virus
Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV
The investigators are studying whether an anti-inflammatory intervention improves impaired coronary endothelial function (CEF) in HIV+ people with no clinical coronary artery disease (CAD).
- Trial name
- NCT02624180
- Testing
- Colchicine
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Johns Hopkins University
HIV/AIDS, Medication Adherence
A Text-Based Adherence Game for Young People Living With HIV in Ghana
This study will develop and evaluate a game-based, text message intervention to promote adherence to HIV care among young people living with HIV (YPLH) in Ghana.
- Trial name
- TAG (NCT03928717)
- Testing
- Text-Based Adherence Game, Standard of Care (SOC)
- Where
- Ghana
- Volunteers
- 60 people
- Sponsor
- Rhode Island Hospital
Sexually Transmitted Diseases, Gonorrhea
Zenyth: Motivational Interviewing-based Telehealth Intervention for Bacterial Sexually Transmitted Infection Screening
In the United States (US), gay and bisexual men living with human immunodeficiency virus (HIV) bear a heavy burden of bacterial sexually transmitted infections (STIs) such as gonorrhea, chlamydia, and syphilis.
- Conditions
- Sexually Transmitted Diseases, Gonorrhea, Chlamydia, Syphilis
- Trial name
- NCT06100250
- Testing
- Motivational interviewing and specimen self-collection
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan
Hiv
Mhealth for PrEP Adherence by Young Adult MSM, Phase 2
This Phase 2 project aims to enhance and test a mobile health intervention designed to increase adherence to the daily PrEP pill among culturally-diverse young adult men who have sex with men.
- Trial name
- NCT04633200
- Testing
- DOT mobile app
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Environment and Health Group, Inc.
HIV Infections, Adolescent Development
Tailored Motivational Interviewing Implementation-Effectiveness Trial in Multidisciplinary Adolescent HIV Care Settings
The goal of this study is to test a multi-faceted Tailored Motivational Interviewing Implementation intervention (TMI), based on the Dynamic Adaptation Process (DAP) to scale up an Evidence-based Practice (EBP) in…
- Conditions
- HIV Infections, Adolescent Development, Care Eliciting Behavior, Patient Non-Compliance
- Trial name
- TMI (NCT03681912)
- Testing
- Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS), Randomized Guided Development of COPs with an internal facilitator after one year of implementation., CoP development without internal facilitation.
- Where
- United States
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Florida State University
Infection, Human Immunodeficiency Virus, HIV Infections
Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers
Cabotegravir (CAB) long-acting (LA) is a promising candidate for human immunodeficiency virus (HIV) pre exposure prophylaxis (PrEP) due to its potent antiretroviral activity and infrequent dosing requirements.
- Trial name
- NCT02478463
- Testing
- Cabotegravir tablet 30 mg once daily for 28 days., Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV
Exercise Training to Improve Brain Health in Older HIV+ Individuals
Management and treatment of older persons living with HIV (PLWH) (≥ 40 years old) is becoming increasingly more complex as a majority is greater than 40 years old.
- Trial name
- Ex/HIV (NCT02663934)
- Testing
- Exercise, Stretching and Social Interaction
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Washington University School of Medicine
Human Immunodeficiency Virus Infection
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
The overall purpose of the study was to describe the real-life adherence, effectiveness and safety of the Kaletra Adherence Support Assistance (KASA) Program in human immunodeficiency virus (HIV)-positive patients who were…
- Trial name
- NCT01662336
- Testing
- Lopinavir / ritonavir, Kaletra Adherence Support Assistance Program
- Volunteers
- 173 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV/AIDS
Triomune Bioequivalence With Innovators
The null hypothesis is that there is a difference in the the relative rate and extent of absorption into the systemic circulation of Triomune and brand-name Stavudine/Lamivudine/Nevirapine in HIV-infected Africans and the…
- Trial name
- NCT01025830
- Testing
- Triomune, Zerit/Epivir/Viramune
- Where
- Uganda
- Volunteers
- 20 people
- Sponsor
- Makerere University
Hiv, Insomnia
HIV-related Insomnia and Inflammation
This randomized trial will determine the effects of internet cognitive behavioral therapy on measures of systemic inflammation in HIV-positive people receiving antiretroviral therapy.
- Trial name
- NCT04721067
- Testing
- SHUTi, Sleep Education/Hygiene
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
HIV Infections, Hepatitis B
Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection
This study will evaluate HIV-HBV infected individuals who have evidence of HBV replication in the blood after taking 48 weeks of more of the HBV active medication tenofovir in combination with emtricitabine or lamivudine.
- Trial name
- NCT00662545
- Testing
- Entecavir with continued standard of care antiretroviral therapy, continued standard of care with tenofovir in addition to emtricitabine or lamivudine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
HIV Infection
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
Many people with HIV fail to regain normal CD4 counts despite effectively suppressing HIV replication with medications. Blocking the "co-receptor" for HIV might decrease inflammation of the immune system, potentially providing an…
- Trial name
- NCT00735072
- Testing
- Maraviroc
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of California, San Francisco
Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
Background: HIV stands for human immunodeficiency virus, which is the virus that causes AIDS. There is currently no licensed vaccine to prevent HIV infection.
- Trial name
- NCT03783130
- Testing
- VRC-HIVRGP096-00-VP, Alum Adjuvant
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.